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Objective: The present study was performed to elucidate the possible role of SIRT1 signaling in joint
inﬂammation in human articular chondrocytes.
Design: Real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) and Western
blotting were performed to detect gene products and proteins involved in tumor necrosis factor
a (TNF-a)-induced inﬂammation and cartilage degradation in human primary chondrocytes. Matrix
metalloproteinase (MMP)-2 and MMP-9 activity was evaluated by gelatin zymography. Overexpression
and knockdown of SIRT1 were also performed to investigate whether SIRT1 is associated with the anti-
inﬂammatory activity of resveratrol in chondrocytes.
Results: Resveratrol dose-dependently inhibited TNF-a-induced cyclooxygenase-2 (COX-2), MMP-1,
MMP-3, MMP-13 and PGE2 production in human chondrocytes. Moreover, MMP-2 and MMP-9 activity
was increased by treatment with TNF-a; however, SIRT1 activation decreased the proinﬂammatory
effects induced by TNF-a. In addition, treatment of SIRT1 activator and overexpression of SIRT1 inhibited
the expression and activation of the main proinﬂammatory regulator NF-kB, which was increased by
TNF-a. When SIRT1 was overexpressed in chondrocytes, the anti-inﬂammatory action of SIRT1 was
similar to that exerted by resveratrol.
Conclusions: SIRT1 activation deacetylates and inactivates NF-kB, and thereby, exerts an anti-
inﬂammatory effect on chondrocytes, suggesting that SIRT1 activators could be explored as potential
treatments for arthritis.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is the common joint disorder and is a leading
cause of disability among the elderly. The disease is characterized
by excessive production of several inﬂammatory mediators has
been observed in OA1. Among these mediators, the proin-
ﬂammatory cytokines interleukin (IL)-1b and tumor necrosis factor
a (TNF-a), which are synthesized locally by synovial cells and
chondrocytes, have been shown to play a central role in sustaining
cartilage damage in arthritis by creating an imbalance between
degradation and repair processes of cartilage2,3. Moreover, TNF-
a has been shown to enhance degradation of the extracellular
matrix (ECM) via activation of matrix metalloproteinases (MMPs).
Degradation of the ECM in articular cartilage is the central eventS.-Y. Park, College of Veteri-
onbuk 561-756, South Korea.
.
s Research Society International. Pthat leads to joint destruction in many arthritic conditions,
including OA4. This proinﬂammatory effect is mediated by the
induction of cyclooxygenase-2 (COX-2), which produces the
inﬂammatory mediator prostaglandin E2 (PGE2)5,6.
The expression and biological activity of the aforementioned
proinﬂammatory factors are regulated by NF-kB. NF-kB regulates
the expression of many genes involved in immune responses and
inﬂammation7. When such cells are stimulated by cytokines,
including IL-1b and TNF-a, which play important roles in the
initiation and development of OA via activation of NF-kB
pathways5,8.
Recent reports showed that SIRT1 is a NADþ-dependent
deacetylase of numerous substrates. SIRT1 has been shown to
mediate a variety of physiological events, including cell survival,
increased metabolic rate, and higher oxygen consumption by
deacetylation of target substrates9,10. For example, SIRT1 deacety-
lates the p53 protein at lysine 382 and represses its transcriptional
function to protect cells from apoptosis11,12. Also, it was recently
shown that SIRT1 proteins levels are reduced in chondrocytes
derived from OA cartilage, compared to those derived from normalublished by Elsevier Ltd. All rights reserved.
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various cell lines including chondrocytes14. Additionally, resvera-
trol, a natural product known to activate a number of cellular
proteins, including SIRT1, was shown to enhance chondrocyte
survival15,16. Taken together, these studies suggest that SIRT1 may
regulate chondrocyte survival in OA cartilage15. Thus, SIRT1 may
conceivably be a key regulator of inﬂammation in mammalian cells
via interaction with proinﬂammatory. In fact, SIRT1 was previously
reported to play important inhibitory roles in sustained inﬂam-
mation and in the aging of lungs17. The reported general anti-
inﬂammatory function of SIRT1 in model organisms suggests that
SIRT1 may prevent the release of proinﬂammatory mediators and
protect against ECM degradation in OA. However, to date, there
have been no reports on the roles of SIRT1 in COX-2, PGE2 andMMP
production as well as activation of human chondrocytes. In this
study, we explored the potential anti-inﬂammatory role of SIRT1 in
human chondrocytes. Our ﬁndings indicate that SIRT1 is a potent
anti-inﬂammatory protein and inhibits the COX-2/ MMP pathway
via suppression of the potent proinﬂammatory factor NF-kB.
Materials and methods
Reagents
Resveratrol, purchased from Sigma (SigmaeAldrich, St. Louis,
MO, USA), was prepared as a 100 mM solution in ethanol.
Recombinant human TNF-a was purchased from Santa Cruz
Biotechnology (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Sirtinol, an SIRT1 inhibitor, was purchased from Sigma.
Chondrocyte isolation and monolayer cultures
Cartilage tissue samples were obtained from the tibial plateaus
of knees from OA patients during joint replacement surgery, after
receiving full informed consent from patients and local ethics
committee approval. Full-thickness cartilage slices were obtained
from a relatively lesion-free area above the subchondral bone.
Human OA chondrocytes were harvested from the discarded knees
as described previously18. Brieﬂy, cartilage slices were chopped and
incubated with 0.25% trypsin for 30 min, followed by 0.1% colla-
genase (SigmaeAldrich, St. Louis, MO, USA; #C6885) treatment for
6 h in DMEM (Invitrogen-Gibco, Grand Island, NY, USA)with 10% (v/
v) fetal bovine serum (FBS) (Invitrogen-Gibco) and antibiotics
(100 mg mL1 penicillinestreptomycin). Thereafter, cells were
seeded in culture ﬂasks in DMEM supplemented with 10% FBS and
antibiotics. These ﬁrst passage chondrocytes were used in subse-
quent experiments. Chondrocytes were incubated with DMEM
containing 1% FBS prior to treatment with 0.5 % ethanol (vehicle
control), resveratrol (12.5 to 200 mM), sirtinol (10 mM) and proin-
ﬂammatory cytokines.
Construction of recombinant adenoviruses
SIRT1-expressing recombinant adenovirus (Ad-SIRT1) was used
for SIRT1 experiments. LacZ-bearing adenovirus (Ad-LacZ) was
used as a control. Recombinant adenoviruses were ampliﬁed in
HEK-293 cells and puriﬁed using the Vivapure AdenoPACK kit
(Sartorius AG, Goettingen, Germany) according to the manufac-
turer’s instructions.
SIRT1 RNA interference
Human chondrocytes were transfected with validated StealthTM
siRNAs (Invitrogen, Carlsbad, CA, USA) directed against SIRT1
(oligo ID VHS50608; Invitrogen) using the Lipofectamine 2000(Invitrogen). Nonspeciﬁc siRNA (oligo ID 12935e300; Invitrogen)
was used as a negative control12.
RT-PCR
Total RNA was extracted from human chondrocytes using the
Easy-spin total RNA extraction kit (iNtRON Biotechnology, Seoul,
Korea). The mRNA expressions of COX-2 and MMPs were analyzed
by RT-PCR using speciﬁc primer sets. The sequences of the primers
used for the RT-PCR were as follows:
COX-2: forward, 50AGTCCCTGAGCATCTACGGTTTG30, reverse, 50
CATCGCATACTCTGTTGTGTTCCC30;
MMP-1: forward, 50TCCACTGCTGCTGCTGCTG30, reverse, 50TTTC
AACTTGCCTCCCATCATTCTTC30;
MMP-3: forward, 50TGAACAATGGACAAAGGATACAACAGG30,
reverse, 50ATCATCTTGAGACAGGCGGAACC30;
MMP-13: forward, 50AGTGGTGGTGATGAAGATGATTTGTC30,
reverse, 50 TCTAAGGTGTTATCGTCAAGTTTGCC30;
b-actin: forward, 50GCAAGCAGGAGTATGACGAG30, reverse, 50CA
AATAAAGCCATGCCAATC30.
The sizes of the products were checked by agarose gel electro-
phoresis. Images thereof were captured using the Fusion FX7
system (Vilber Lourmat, Eberhardzell, Germany).
Real-time quantitative reverse transcription polymerase chain
reaction (qRT-PCR)
Total RNA was extracted from chondrocytes using the Easy-
spin total RNA extraction kit (iNtRON Biotechnology, Seoul,
Korea). qRT-PCR was performed using 1 ml of SYBR Green Master
mix (Bio-Rad Laboratories, Hercules, CA, USA) primers to a total
reaction volume of 20 ml. The sequences of the primers used for the
qRT-PCR were as follows:
COX-2: forward, 50AGTCCCTGAGCATCTACGGTTTG30, reverse, 50
CATCGCATACTCTGTTGTGTTCCC30;
MMP-1: forward, 50TCCACTGCTGCTGCTGCTG30, reverse, 50TTTC
AACTTGCCTCCCATCATTCTTC30;
b-actin (as an internal control): forward, 5’GCAAGCAGGAGTATG
ACGAG3’, reverse, 50CAAATAAAGCCATGCCAATC30.
All reactions were performed with iTaq SYBR Green Supermix
(Bio-Rad Laboratories) using the CFX96 real-time PCR detection
system (Bio-Rad Laboratories).
Western blot
Chondrocytes were lysed in buffer (25 mM HEPES, pH 7.4,
100 mMNaCl, 1 mM ethylenediaminetetraacetic acid (EDTA), 5 mM
MgCl2, 0.1 mM DTT, and a protease inhibitor mixture). Equal
amounts of lysate protein were electrophoretically resolved by 10e
15% sodium dodecyl sulfate (SDS)-polyacrylamide gel electropho-
resis (SDS-PAGE). Images thereof were captured using the Fusion
FX7 system (Vilber Lourmat, Eberhardzell, Germany). The densi-
tometry of the signal bands was analyzed using Bio-1D software
(Vilber Lourmat, Marne La Vallee, France). Antibodies against COX-
2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), p-65 (Millipore),
acetyl p-65 (Cell Signaling Technology, Beverly, MA, USA), SIRT1
(Santa Cruz Biotechnology) and ß-actin (SigmaeAldrich, St. Louis,
MO, USA) were used to perform the immunoblotting experiments.
Immunoﬂuorescent staining
Cells were cultured on glass slides, ﬁxed with cold acetone,
blocked by 5% FBS in TBST. They were incubated with mouse NF-kB
(active p-65 subunit) antibody (Millipore), goat COX-2 antibody
(Santa Cruz Biotechnology), and rabbit SIRT1 antibody (Santa Cruz
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conjugated with Alexa Fluor 488, anti-goat IgG conjugated with
Alexa Fluor 350 and anti-rabbit IgG conjugated with Alexa Fluor
546. Thereafter, cells were observed under a ﬂuorescence micro-
scope (Nikon ECLIPSE 80i, Nikon Corporation).
Quantiﬁcation of glycosaminoglycan (GAG) release
Cartilage explants were treated with TNF-a with or without
resveratrol for 72 h. GAG levels in the culture media were then
determined by reacting samples with 1,9-dimethylmethylene blue.
Thereafter, 20 ml of sample media or chondroitin sulfate were
mixedwith 180 ml of DMB reagents (48mg/ml DMB, 40mMglycine,
40 mM NaCl, 10 mM HCl, pH 3.0) at room temperature. Absorbance
at 525 nm was then measured with a spectrophotometer (Spec-
tramax, Molecular Devices, Sunnyvale, CA, USA). All measurements
were performed in quadruplicate. Quantiﬁcation was performed
using a standard curve of chondroitin sulfate. Results were
normalized to protein concentrations of GAG release.
Analysis of PGE2 levels via enzyme-linked immunosorbent assay
(ELISA)
Chondrocytes were incubated with DMEM containing 1% FBS
prior to treatment with or without TNF-a (10 ng/ml), resveratrol
and sirtinol for 24 h. PGE2 levels in the culture media were quan-
tiﬁed using an immunoenzymatic method (PGE2 EIA kits, Cayman
Chemicals, Ann Arbor, MI, USA) according to the manufacturer’s
speciﬁcations.
Gelatin zymography
The supernatant was resolved on SDS-PAGE gels containing 10%
acrylamide and 1 mg/ml gelatin. The gels were then washed with
2.5% (w/v) Triton X-100 at room temperature and incubated over-
night in a developing buffer containing 50 mM TriseHCl (pH 7.5),
0.2 M NaCl and 5mM CaCl2. Gels were stained with 0.2% Coomassie
Blue R-250 in 50% ethanol and 10% acetic acid at room temperature
and destained with a buffer comprising 20% methanol, 10% acetic
acid at room temperature. The gels were analyzed using the Fusion
FX7 system (Vilber Lourmat, Eberhardzell, Germany).
Statistical evaluation
All data were expressed as mean  standard deviation (SD) and
analyzed by one-way analysis of variance (ANOVA) with Tukey’s
post test for multiple groups using GraphPad Prism Version 5.0.
Means sharing a common alphabetical symbol indicate not signif-
icantly different values.
Results
1. Resveratrol, an SIRT1 activator, inhibits TNF-a-induced
inﬂammatory factor release and ECM degradation
The proinﬂammatory cytokine TNF-a contributes to the patho-
genesis of OA and is a potent enhancer of COX-2, which plays
a pivotal role in the cartilage inﬂammation5,19e22. Consistent with,
cells exposed to TNF-a resulted in increase in COX-2 mRNA
expression [Fig. 1(A) and (B)]. As anticipated, the treatment of
resveratrol prevented TNF-a-induced COX-2 mRNA expression in
a concentration-dependent manner [Fig. 1(A) and (B)].
As up-regulation and activation of MMP expression has been
associated with a loss of cartilage matrix23, we investigated the
effect of resveratrol on MMP production and activation. A previousstudy found that MMP-1, MMP-3 and MMP-13 were detectable in
OA synovial ﬂuids and were produced in vitro by both the synovium
and chondrocytes in response to inﬂammatory cytokines2.
Consistent with the results from that study, we found that TNF-
a treatment induced signiﬁcant up-regulation of MMP-1, MMP-3
and MMP-13 mRNA expression. Additionally, resveratrol treatment
dose-dependently decreased the observed TNF-a-induced increase
in MMP mRNA expression [Fig. 1(C)]. Moreover, through gelatin
zymography, we indentiﬁed that resveratrol prevented the TNF-a-
induced activation of MMP-2 and MMP-9 [Fig. 1(D)]. Accordingly,
these results indicated that resveratrol exerts anti-inﬂammatory
effects by decreasing the expression of COX-2 and MMPs.
To further evaluate the chondroprotective effect of resveratrol
treatment, we investigated whether resveratrol would prevent
TNF-a-induced degradation of cartilage matrix. When cartilage
explants were treated with TNF-a, the amounts of GAG released
from cartilage explants into the media were signiﬁcantly increased.
Meanwhile, the treatment of resveratrol successfully inhibited
TNF-a-induced increase in GAG release from cartilage explants
[Fig. 1(E)]. These results indicate that resveratrol was effective in
preventing TNF-a-mediated release of GAG into the media of
cartilage explant cultures.
2. SIRT1 protein up-regulation by resveratrol protects against
TNF-a in human chondrocytes
Resveratrol increases the deacetylase activity of several sirtuin
members, including the mammalian ortholog SIRT1, which is
known to exhibit anti-inﬂammatory activity17,24. To investigate
whether resveratrol regulates SIRT1 protein expression and
deacetylase activity, human chondrocytes were treated with
resveratrol at concentrations of 12.5, 50 and 200 mM. Resveratrol
increased SIRT1 protein expression in a dose-dependent manner
and this was blocked by the SIRT1 inhibitor, sirtinol [Fig. 2(A) and
(B)]. Remarkably, treatment with TNF-a resulted in a down-regu-
lation in SIRT1 protein expression, which was reversed by treat-
ment with resveratrol [Fig. 2(B)].
SIRT1 interacts with and regulates histones and various tran-
scription factors, such as NF-kB p-65 and FOXO. Since activation of
NF-kB is known to play a pivotal role in the development of OA and
to lead to ECM damage and cartilage destruction7, it was hypoth-
esized that this factor may be involved in the resveratrol-induced
anti-inﬂammatory activity observed in human articular chon-
drocytes. Accordingly, we assessed whether resveratrol contributes
to the deacetylation of p-65. As shown in Figs. 2(C) and 3(A),
acetylation of p-65 was dose-dependently reduced in resveratrol-
pretreated cells and this reduction was blocked by the SIRT1
inhibitor sirtinol.
We further investigatedwhether activated SIRT1 regulates other
proteins potentially associated with inﬂammation. Accordingly,
resveratrol decreased the expression of the proinﬂammatory
protein COX-2 [Fig. 3(B)]. The reduction in COX-2 protein expres-
sion by resveratrol was prevented by sirtinol [Fig. 3(B)]. This
suggests that SIRT1 may be involved in the resveratrol-mediated
inhibition of inﬂammatory cytokine production.
3. Knockdown of SIRT1 by siRNA suppresses resveratrol-
mediated anti-inﬂammatory activity
To conﬁrm the relationship between SIRT1, NF-kB p-65 and
COX-2 inactivation, we used siRNA to inhibit SIRT1 in human
articular chondrocytes and determined the effects of SIRT1
knockdown on the resveratrol-mediated anti-inﬂammatory effect
against TNF-a. Human articular chondrocytes were transfected
with either SIRT1 siRNA and treated with TNF-a (50 ng/ml) and/or
Fig. 1. Resveratrol, an SIRT1 activator, prevents TNF-a-induced COX-2 and MMP expression and activation, as well as GAG release. (AeC), Chondrocytes were pretreated with
increasing concentrations of resveratrol for 1 h, and then stimulated with TNF-a (50 ng/ml) for 12 h. Thereafter, total RNA was isolated and cDNA was synthesized. COX-2 (A, B) and
MMP-1, 3 and 13 (C) mRNA levels were quantiﬁed using RT-PCR and real-time RT-PCR (B). The results were adjusted according to b-actin and expressed as relative density units (B).
b-actin gene expressionwas used for normalization (A and C). (D), Upper, chondrocytes were treated as described in (A), and MMP activation in the concentrated conditioned media
was analyzed 24 h after TNF-a treatment using gelatin zymography. The lower panels show blots that were stripped and re-probed with speciﬁc anti-b-actin antibodies. The bar
graph indicates the mean  SD (n ¼ 3). The data were analyzed using ANOVA and Tukey multiple range tests (P < 0.01). Means sharing a common alphabetical symbol did not
signiﬁcantly differ. (E), Human cartilage explants were treated for 72 h with the indicated concentrations of resveratrol and TNF-a (50 ng/ml). GAG released into the culture media
was assessed using dimethylmethylene blue. The data are results from three different experiments. The data were analyzed using ANOVA and Tukey multiple range tests (P < 0.01).
Means sharing a common alphabetical symbol did not signiﬁcantly differ.
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level was markedly decreased in SIRT1 siRNA-treated cells relative
to control siRNA-treated cells [Fig. 4(C and D)]. Moreover, SIRT1
mRNA level was markedly increased by treatment with resveratrol
in control siRNA-treated cells, while knockdown of SIRT1 led to
reduced levels of SIRT1 mRNA compared to those treated with
control siRNA. However, there was no change in SIRT1 mRNA
expression level after resveratrol stimulation in SIRT1 siRNA-
treated cells [Fig. 5(A)]. In accordance with the above ﬁndings
regarding the effect of sirtinol on COX-2 protein expression,
resveratrol, an SIRT1 inhibitor, completely lost its ability to impair
proinﬂammatory factor activationwhen SIRT1 was silenced (Fig. 4).
Furthermore, although TNF-a treatment signiﬁcantly increased
p-65 acetylation and activation [Fig. 4(A)], as well as COX-2 mRNA
[Fig. 5(B)] and protein expression [Fig. 4(B) and (D)], pretreatment
with resveratrol impaired the activation of these proinﬂammatory
factors. However, silencing of SIRT1 resulted in no change in TNF-a-
induced p-65 activation and COX-2 up-regulation (Fig. 4).
Next, we evaluated whether resveratrol-induced down-regula-
tion of the expression of major MMPmRNAs, which are involved in
ECM degradation, is a SIRT1-mediated process. Knockdown of
SIRT1 using siRNA restored MMP-1 and MMP-13 mRNA levels tothose observed in TNF-a treated cell [Fig. 5(C) and (D)]. In addition,
down-regulation of SIRT1 prevented the inhibitory effect of
resveratrol on proinﬂammatory factor expression and activation,
indicating that SIRT1 is responsible for the association between
resveratrol and chondrocyte protection against TNF-a.
4. Adenoviral overexpression of SIRT1 results in anti-
inﬂammatory activity
To directly ascertain the anti-inﬂammatory role of SIRT1 in the
TNF-a-induced proinﬂammatory response observed in human
chondrocytes, cells were infected with adenoviruses expressing
SIRT1 at multiplicity of infections (M.O.I.) of 50, 100, and 200 pfu/
cell, and treatedwith 50 ng/ml of TNF-a. SIRT1-overexpressing cells
showed a remarkable increase in SIRT1 protein at an M.O.I. of 200
pfu/cells compared to those observed in control cells [Fig. 6(A) and
(E)]. Overexpression of SIRT1 signiﬁcantly rescued the rate of TNF-
a-mediated NF-kB p-65 activation via acetylation and phosphory-
lation of p-65 [Fig. 6(B) and (E)]. In addition, a concentration-
dependent decrease in COX-2 expression at the transcriptional
level [Fig. 6(C)], as well as the protein level [Fig. 6(D) and (E)],
was also observed in SIRT1-overexpressing human articular
Fig. 2. SIRT1 is involved in the protective effect of resveratrol in chondrocytes. (A), Western blot analysis of SIRT1 expression in chondrocytes exposed to resveratrol (24 h) with
or without sirtinol (10 mM), an SIRT1 inhibitor. The lower panel illustrates the quantiﬁcation of SIRT1. The results were adjusted based on b-actin and expressed as relative density
units. (B), Representative immunoblots showing SIRT1 protein levels in the chondrocytes pretreated with resveratrol (from 12.5 mM to 200 mM) for 1 h before TNF-a (50 ng/ml) and/
or sirtinol (10 mM) for 24 h. The lower panel illustrates the quantiﬁcation of SIRT1. The results were adjusted based on b-actin and expressed as relative density units. (C), Western
blot analysis of acetyl p53, acetyl p-65 and the active form of NF-kB p-65 in chondrocytes exposed to resveratrol (24 h) with or without the SIRT1 inhibitor sirtinol (10 mM). The
lower panel illustrates the quantiﬁcation of p-65 acetylation. The results were adjusted based on b-actin and expressed as relative density units. The bar graph indicates the
mean  SD (n ¼ 3). The data were analyzed using ANOVA and Tukey multiple range tests (P < 0.01). Means sharing a common alphabetical symbol did not signiﬁcantly differ.
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infected cells was unchanged compared with TNF-a-treated
chondrocytes [Fig. 6(D) and (E)]. The morphology of SIRT1-
overexpressing cells appeared normal and indistinguishable from
that of Ad-LacZ-infected cells [Fig. 7(E)].
TNF-a is known to stimulate the production of MMPs, enzymes
that have been shown to degrade all components of the ECM. Not
surprisingly, MMP production and activation have been shown to
play an important role in OA progression25,26. To determine
whether the chondroprotective effects of SIRT1might be associated
with a disturbance in MMP expression, MMPmRNA expressionwas
analyzed in human chondrocytes infected with Ad-SIRT1 or
Ad-LacZ and exposed to TNF-a (50 ng/ml) for 12 h. Quantitative
RT-PCR experiments revealed that overexpression of SIRT1 signif-
icantly reduced the mRNA expressions of MMP-1, MMP-3 and
MMP-13 in human chondrocytes treated with TNF-a (Fig. 7).
Together, these results provide further evidence that the anti-
inﬂammatory effects of resveratrol are due to the down-
regulation of NF-kB p-65/COX-2/MMPs pathways via activation of
SIRT1, suggesting that SIRT1 may play a pivotal role in chon-
droprotection against proinﬂammatory cytokines.
5. SIRT1 regulates PGE2 production in TNF-a-mediated
inﬂammation
PGE2, which originates from activation of the COX pathways, is
produced by OA chondrocytes and can promote matrix degenera-
tion15,27. Accordingly, we further evaluated the chondroprotectiveeffect of SIRT1 by assessing PGE2 production in culture media
[Fig. 8(A) and (B)]. The production of PGE2 was increased by stim-
ulation of TNF-a in the supernatants of conditionedmedia [Fig. 8(A)
and (B)]. After treatment with resveratrol, PGE2 synthesis was
signiﬁcantly reduced to the level of the control group [Fig. 8(A)].
Next, we investigated whether the action of resveratrol is
mediated by SIRT1. Selective knockdown of SIRT1 using siRNA
abolished the observed resveratrol-stimulated reduction in TNF-a-
mediated PGE2 production [Fig. 8(A)]. To further study the direct
relationship between SIRT1 and PGE2 production, we used an
adenovirus vector system to overexpress SIRT1 proteins. Over-
expression of SIRT1 signiﬁcantly rescued the up-regulation of PGE2
production caused by TNF-a [Fig. 8(B)] (treatment with 0.9 ng/ml
TNF-a vs infection with 0.5 ng/ml Ad-SIRT1 before TNF-a treat-
ment; P < 0.05). As expected, LacZ vector infection in human
chondrocytes demonstrated no effect on PGE2 production. These
results suggest that resveratrol prevents inﬂammatory cytokine-
induced PGE2 synthesis via activation of SIRT1.
Discussion
Sirtuin 1 (SIRT1) is known to deacetylate histones and non-
histone proteins, including transcription factors, thereby regu-
lating metabolism and inﬂammation-immune function28. SIRT1
was previously shown to act as a novel immunomodulator in
chronic inﬂammatory diseases, such as diabetes and colitis by
modulating the NF-kB-dependent pathway28. Furthermore, it also
inhibited the expression of various genes that encode other
Fig. 3. Inhibition of SIRT1 abolishes resveratrol-mediated chondrocyte protection against TNF-a. (A and B), Resveratrol and/or sirtinol 10 mM were added to the chondrocytes
1 h before stimulation with TNF-a (50 ng/ml) for 24 h. Cell lysates were prepared and analyzed for acetyl p-65, p-65 (A) and COX-2 (B) protein expression by Western blotting. The
lower panel illustrates the quantiﬁcation of acetyl p-65 and COX-2 proteins. The results were adjusted based on b-actin and expressed as relative density units. The bar graph
indicates the mean  SD (n ¼ 3). The data were analyzed using ANOVA and Tukey multiple range tests (P < 0.01). Means sharing a common alphabetical symbol did not signiﬁcantly
differ.
Fig. 4. SIRT1 regulates COX-2 expression and p-65 activation via deacetylation of p-65. (AeD), Human articular chondrocytes were transfected with either SIRT1 siRNA or
negative control siRNA for 24 h. Resveratrol (200 mM) was added to the chondrocytes 1 h before stimulation with TNF-a (50 ng/ml) for 24 h. After 24 h, the expression of active p-65
(A), COX-2 (B), and SIRT1 (C) proteins were examined by immunocytochemistry. (D), Western blot analysis of SIRT1, COX-2, acetyl p-65 and p-65 activation in the chondrocytes
treated as described in (AeC). Expression levels were determined by Western blot analysis and b-actin was used as a loading control. The experiments were repeated three times to
conﬁrm the results. The data represent samples from three different experiments.
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Fig. 5. Silencing of SIRT1 abolishes the anti-inﬂammatory action of resveratrol in chondrocytes. (AeD), Human articular chondrocytes were transfected with either SIRT1 siRNA
or negative control siRNA for 24 h. Resveratrol (200 mM) was added to the chondrocytes 1 h before stimulation with TNF-a (50 ng/ml) for 12 h. Cell lysates were prepared and
analyzed for SIRT1 (A), COX-2 (B), MMP-1 (C) and MMP-13 (D) mRNA expression by real-time RT-PCR. The results were adjusted according to b-actin and expressed as relative
density units. The bar graph indicates the mean  SD (n ¼ 3). The data were analyzed using ANOVA and Tukey multiple range tests (P < 0.01). Means sharing a common alphabetical
symbol did not signiﬁcantly differ.
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regulation of NF-kB15,28e30. However, the role of SIRT1 in OA
pathogenesis has primarily been studied with respect to chon-
drocyte apoptosis14,15,31, while the anti-inﬂammatory effect of
SIRT1 in chondrocytes remains largely unknown.
In this study, we investigated the effects of SIRT1 on chon-
drocytemetabolism, particularly on the catabolic effects induced by
the OA-associated TNF-a. We found that SIRT1 acts as a negative
regulator of inﬂammation and that SIRT1 activity is mediated by
the NF-kB/COX-2/MMPs pathway. Furthermore, we have also
demonstrated that treatment with the resveratrol effectively
inhibited the activation of proinﬂammatory factors by activating
SIRT1, leading to deacetylation of NF-kB p-65 and subsequent
down-regulation of TNF-a-induced COX-2 and MMP expression in
articular chondrocytes.
Resveratrol was the ﬁrst polyphenolic compound shown to
activate SIRT1, and is well known to exhibit anti-inﬂammatory
activity32,33. Furthermore, we have also demonstrated that treat-
ment with the resveratrol effectively inhibited the activation of
proinﬂammatory factors by activating SIRT1, leading to deacetyla-
tion of NF-kB p-65 and subsequent down-regulation of TNF-a-
induced COX-2 and MMP expression in articular chondrocytes.
Proinﬂammatory cytokines such as TNF-a and IL-1b have been
shown to mediate cartilage degradation in OA in humans as well as
in animals2. Previously, TNF-awas found to stimulate transcription
of a smaller inactive SIRT1 protein product (an enzymatically
inactive Sirt1 fragment the size of 75 kD) by cleavage of normal
SIRT134. Consistent with this ﬁnding, we observed that SIRT1mRNA
levels were increased by TNF-a treatment [Fig. 5(A)].
Also, TNF-a is known to activate ubiquitous NF-kB, leading to
further production and up-regulation of proinﬂammatory cyto-
kines and enzymes such as COX-2 and MMPs, which in turnproduce prostaglandins (PGs) and degrade ECM macromolecules,
promoting cartilage degradation and further joint inﬂammation35.
MMP-1 is expressed in various cell types, including chondrocytes
and ﬁbroblasts, and is most effective in degrading type III collagen.
MMP-13 is expressed mainly by articular chondrocytes, and pref-
erentially cleaves type II collagen as well as aggrecan, a proteo-
glycan important for the resiliency of normal articular
cartilage25,26,36,37. The collagenases, MMP-1 and MMP-13, play
predominant roles in RA and OA because they are rate-limiting
factors in the process of collagen degradation25,26,36. Thus, they
are postulated to also play an important role in the destruction of
cartilage.
Since MMP induction is considered a key mediator of cartilage
destruction, we assessed the inﬂuence of SIRT1 on MMP produc-
tion. As expected, activation of SIRT1 by resveratrol treatment
reduced MMP-1 and MMP-13 production, as well as MMP-2 and
MMP-9 activation, which were signiﬁcantly blocked by SIRT1 siRNA
(Fig. 5). Moreover, overexpression of SIRT1 signiﬁcantly decreased
TNF-a-induced production and activation of MMP (Fig. 7). In
addition to collagen, MMP-13 also degrades the proteoglycan
molecule, aggrecan, giving it a dual role in matrix destruction. The
expression of other MMPs, such as MMP-2, MMP-3 andMMP-9, has
also been shown to be elevated in arthritis, as these enzymes
degrade the non-collagen matrix components of joints25,26,36. In
this study, resveratrol treatment was shown to reduce MMP-13
mRNA expression level, and provide protection against proteo-
glycan destruction [Fig. 1(E)]. Accordingly, these results suggest
that SIRT1 inhibits the ECM degradation caused by proin-
ﬂammatory cytokines by reducing MMP production and activation.
NF-kB activation plays a major role in OA progression. The
nuclear function of the heterodimeric NF-kB transcription factor is
regulated in part by the reversible acetylation of its RelA subunit.
Fig. 6. SIRT1 overexpression suppresses TNF-a-induced inﬂammatory factors in human chondrocytes via inhibition of p-65 expression. (AeE), Human chondrocytes infected
with adenoviruses expressing LacZ (M.O.I. of 200 pfu/cell) or SIRT1 (M.O.I. of 200 pfu/cell, and indicated on the blot) for 48 h were treated with or without TNF-a (50 ng/ml) for 12 h
(C) or 24 h (A, B, D and E). SIRT1, acetyl p-65, p-65 and COX-2 protein expression levels were determined by Western blot analysis (A, B and D) and immunocytochemistry (E). b-
actin was used as a loading control. Total RNA was isolated and COX-2 (C) mRNA was quantiﬁed using real-time RT-PCR. The experiments were repeated three times to conﬁrm the
results. The data represent the results of three different experiments.
M.-H. Moon et al. / Osteoarthritis and Cartilage 21 (2013) 470e480 477Acetylation of lysine 310 is required for full transcriptional activity
of RelA38e40. This process is reciprocally regulated by histone
deacetylases (HDACs), in fact, several HDAC inhibitors have been
shown to activate NF-kB. In the present study, we demonstrated
that TNF-a enhances the activation of NF-kB p-65, and that
resveratrol decreased the acetylation of NF-kB p-65. Interestingly,
whereas blockade of SIRT1 using sirtinol or siRNA signiﬁcantlyinhibited the resveratrol-induced deacetylation of NF-kB p-65
(Figs. 4 and 5), overexpression of SIRT1 induced the inactivation
and deacetylation of NF-kB p-65 (Figs. 6 and 7). These results
suggest that the anti-inﬂammatory activity of SIRT1 (i.e., down-
regulation of MMPs and COX-2) stems from the inhibition of
NF-kB activation, given the crucial role of NF-kB p-65 in MMP
production.
Fig. 7. Inhibition of TNF-a-induced up-regulation of MMP mRNA by SIRT1 overexpression. (AeC), Chondrocytes were infected with Ad-SIRT1 or Ad-LacZ for 48 h before
treatment with TNF-a (10 ng/ml). Total RNA was isolated 24 h after cytokine stimulation and real-time RT-PCR was performed using MMP-1 (A), MMP-3 (B) and MMP-13 (C) primer
sets. The bar graph indicates the mean  SD (n ¼ 4). The data were analyzed using ANOVA and Tukey multiple range test (P < 0.01). Means sharing a common alphabetical symbol
did not signiﬁcantly differ.
M.-H. Moon et al. / Osteoarthritis and Cartilage 21 (2013) 470e480478COX-2, one of the classic NF-kB targets, is known as the rating-
limiting enzyme in PG production. In addition, as observed in this
study, the protective effects of SIRT1 on ECM metabolism were
consistent with its capacity to inhibit TNF-a-mediated production
of PGE2. Previous studies have shown that the addition of PGE2
upregulates MMP-1 synthesis both in chondrocytes and in synovial
ﬁbroblasts15. Our results showed that while overexpression of
SIRT1 dramatically decreased PGE2 production, silencing of SIRT1
signiﬁcantly abolished the activity of SIRT1, increasing PGE2 level toFig. 8. Inhibitory effect of resveratrol on PGE2 synthesis via selective activation of SI
negative control siRNA for 24 h. Resveratrol (200 mM) was added to the chondrocytes 1 h bef
PGE2 productionwas quantiﬁed by ELISA. (B), Human chondrocytes infected with adenovirus
treated with or without TNF-a (10 ng/ml) for 24 h. Culture supernatants were collected an
(n ¼ 3). The data were analyzed using ANOVA and Tukey multiple range test (P < 0.01). Mthat of the control group (Fig. 8). PGE2 synthesis was, accordingly,
discerned to be regulated by SIRT1, and increased PGE2 level
resulted in MMP production. Furthermore, while knockdown of
SIRT1 abolished the ability of SIRT1 to inhibit MMP-1 and MMP-13
mRNA expression (Fig. 5), overexpression of SIRT1 reduced MMP
expression in an M.O.I.-dependent manner (Fig. 7).
In conclusion, the results of this study show that SIRT1 inhibits
inﬂammatory responses in human articular chondrocytes, as
conﬁrmed by a reduction in GAG release and a reduction in theRT1. (A), Human articular chondrocytes were transfected with either SIRT1 siRNA or
ore stimulation with TNF-a (10 ng/ml) for 12 h. Culture supernatants were collected and
es expressing LacZ (M.O.I. of 200 pfu/cell) or SIRT1 (M.O.I. of 200 pfu/cell) for 48 h were
d PGE2 production was determined by ELISA. The bar graph indicates the mean  SD
eans sharing a common alphabetical symbol did not signiﬁcantly differ.
M.-H. Moon et al. / Osteoarthritis and Cartilage 21 (2013) 470e480 479expressions of COX-2, PGE2 and MMPs, using siRNA and adenoviral
vector transfection techniques. Accordingly, SIRT1 was discerned to
function as an anti-inﬂammatory compound in human chon-
drocytes. In addition, NF-kB p-65 was shown to be responsible for
the anti-inﬂammatory activity of SIRT1. These results suggest that
SIRT1 activation might be a potential therapeutic target in OA.
Therefore, development of SIRT1-speciﬁc activators including
resveratrol may show promise as potential medical interventions.
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